Protocol Ledger

NCT04143724 · Phase II · RECRUITING

Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

Interventional Phase II clinical trial protocol NCT04143724 sponsored by Bristol Myers Squibb in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-11-07 Enrollment: 99 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04143724
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)99 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04143724
Protocol FieldVerified Registry Value
NCT IdentifierNCT04143724
Consolidated Lead SponsorBristol Myers Squibb
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment99 participants (ESTIMATED)
Registered Start Date2019-11-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI